| Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. | |
| | |
MedLine Citation:
|
PMID: 21068672 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. Serial Kaposi sarcoma biopsies assessed treatment effects on angiogenic factors and Kaposi sarcoma herpesvirus-latency associated nuclear antigen-1 (KSHV-LANA). We observed marked heterogeneity of KSHV-LANA expression. Although the small number of subjects whose response could be evaluated precluded definitive assessment of halofuginone's efficacy, we observed a significant decrease in type-I collagen only in halofuginone-treated lesions, but no effect on MMP-2. The trial design is applicable to future studies of topical agents. |
| | |
Authors:
|
Henry B Koon; Barbara Fingleton; Jeannette Y Lee; Julia T Geyer; Ethel Cesarman; Robert A Parise; Merrill J Egorin; Bruce J Dezube; David Aboulafia; Susan E Krown |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of acquired immune deficiency syndromes (1999) Volume: 56 ISSN: 1944-7884 ISO Abbreviation: J. Acquir. Immune Defic. Syndr. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-14 Completed Date: 2011-01-11 Revised Date: 2012-01-04 |
Medline Journal Info:
|
Nlm Unique ID: 100892005 Medline TA: J Acquir Immune Defic Syndr Country: United States |
Other Details:
|
Languages: eng Pagination: 64-8 Citation Subset: IM; X |
Affiliation:
|
Ireland Cancer Center, Case Western Reserve University, Cleveland, OH, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
AIDS-Related Opportunistic Infections
/
drug therapy* Administration, Topical Adult Antineoplastic Agents / administration & dosage, therapeutic use* Female Humans Male Middle Aged Piperidines / administration & dosage, therapeutic use* Quinazolinones / administration & dosage, therapeutic use* Sarcoma, Kaposi / drug therapy* Single-Blind Method Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
U01 CA070054-09/CA/NCI NIH HHS; U01 CA121947-03/CA/NCI NIH HHS; UO1 CA121947/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Piperidines; 0/Quinazolinones; 17395-31-2/halofuginone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Unleashing the power of human genetic variation knowledge: New Zealand stakeholder perspectives.
Next Document: Effect of hormonal contraceptive use before HIV seroconversion on viral load setpoint among women in...